Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Serena Bazzurri"'
Autor:
Anna Maria Frezza, Hugh Leonard, Ninna Aggerholm-Pedersen, Giuseppe Badalamenti, Paolo Baili, Giacomo G Baldi, Sebastian Bauer, Serena Bazzurri, Irene Benzonelli, Alexia Bertuzzi, Jean-Yves Blay, Giuseppe Bianchi, Simone Bonfarnuzzo, Christophe Bouvier, Kyetil Boye, Javier Martin Broto, Antonella Brunello, Domenico Campanacci, Paolo G Casali, Carlo Cicala, Elisa Crotti, Lorenzo D'Ambrosio, Angelo Paolo Dei Tos, Nils Dieckmann, Armelle Dufresne, Stephanie Elston, Virginia Ferraresi, Stefano Gabellini, Claudia Giani, Vincenzo Giannusa, Melissa Gil Sanjines, Teresa Grassani, Alessandro Gronchi, Paolo Lasalvia, Stefan Lindskog, Nadia Hindi, Matilde Ingrosso, Andrei Ivanescu, Robin Jones, Iwona Lugowska, Julia Ketzer, Anna Mariuk-Jarema, Alessandro Mazzocca, Laura Monteleone, Carlo Morosi, Andrea Napolitano, Francesca Nardozza, Elisabetta Neri, Maria Nilsson, Andri Papakonstantinou, Sandro Pasquali, Marta Sbaraglia, Federico Scolari, Joanna Szkandera, Claudia Valverde, Bruno Vincenzi, Salvatore Vizzaccaro, Federica Zuccheri, Silvia Stacchiotti, Annalisa Trama
Publikováno v:
PLoS ONE, Vol 19, Iss 8, p e0308387 (2024)
IntroductionEpithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma, marked by distinctive molecular and pathological features and with a variable clinical behavior. Its natural history is still partially understood, reliable prognostic and p
Externí odkaz:
https://doaj.org/article/437c63f0b21f4d4db2adca8416449656
Autor:
Riccardo Marconcini, Paolo Fava, Amedeo Nuzzo, Simona Manacorda, Marco Ferrari, Francesco De Rosa, Michele De Tursi, Enrica Teresa Tanda, Francesca Consoli, Alessandro Minisini, Nicola Pimpinelli, Francesca Morgese, Melissa Bersanelli, Marco Tucci, Maristella Saponara, Alessandro Parisi, Marcella Ocelli, Serena Bazzurri, Giulia Massaro, Riccardo Morganti, Isabella Ciardetti, Ignazio Stanganelli
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundBRAF and MEK inhibitors target therapies (TT) and AntiPD1 immunotherapies (IT) are available first-line treatments for BRAF v600 mutant metastatic melanoma patients. ECOG PS (E), baseline LDH (L), and baseline number of metastatic sites (N)
Externí odkaz:
https://doaj.org/article/7ed0a33bb9c64531ab12915da799b5dc
Autor:
Amedeo Nuzzo, Simona Manacorda, Enrico Sammarco, Andrea Sbrana, Serena Bazzurri, Federico Paolieri, Fiorella Manfredi, Chiara Mercinelli, Marco Ferrari, Giulia Massaro, Adele Bonato, Alessia Salfi, Luca Galli, Riccardo Morganti, Andrea Antonuzzo, Chiara Cremolini, Gianluca Masi
Publikováno v:
Vaccines, Vol 10, Iss 6, p 892 (2022)
Background: Severe acute respiratory syndrome coronavirus 2 disease (COVID-19) has caused a worldwide challenging and threatening pandemic. Multinational, placebo-controlled, observer-blinded trials were conducted since the beginning of pandemic beca
Externí odkaz:
https://doaj.org/article/d8317c50aa9843788fbf947394e22fdc
Autor:
Edoardo Francini, Fang-Shu Ou, Stefano Lazzi, Roberto Petrioli, Andrea G. Multari, Guido Pesola, Luciana Messuti, Elena Colombo, Virginia Livellara, Serena Bazzurri, Sara Cherri, Salvatora T. Miano, Eric G. Wolfe, Steven R. Alberts, Joleen M. Hubbard, Harry H. Yoon, Guido Francini
Publikováno v:
Translational Oncology, Vol 14, Iss 2, Pp 100973- (2021)
Background: High tumor infiltrating lymphocytes (TILs) density was previously shown to be associated with favorable prognosis for patients with colon cancer (CC). However, the impact of TILs on overall survival (OS) of stage II CC patients who receiv
Externí odkaz:
https://doaj.org/article/bb727b9e9ca8480e8ece3bee7ce744b5
Autor:
Anne Sophie Kubasch, Rebekka Wehner, Serena Bazzurri, Antje Tunger, Sebastian Stasik, Marlene Garzarolli, Jörn Meinel, Gustavo Baretton, Friedegund Meier, Christian Thiede, Marc Schmitz, Uwe Platzbecker
Publikováno v:
Blood Advances, Vol 2, Iss 11, Pp 1187-1190 (2018)
Externí odkaz:
https://doaj.org/article/8f6cfaa31b244b91acf27d6bfcfd1a00
Autor:
Edoardo Francini, Virginia Livellara, Steven R. Alberts, Guido Francini, Guido Pesola, Eric G. Wolfe, Fang-Shu Ou, Joleen M. Hubbard, Elena Colombo, Sara Cherri, Roberto Petrioli, Luciana Messuti, Stefano Lazzi, Salvatora Tindara Miano, Harry H. Yoon, Andrea Giovanni Multari, Serena Bazzurri
Publikováno v:
Translational Oncology
Translational Oncology, Vol 14, Iss 2, Pp 100973-(2021)
Translational Oncology, Vol 14, Iss 2, Pp 100973-(2021)
Highlights • Low CD3+ TILs rate was associated with shorter OS in those with stage II colon cancer who did not receive adjuvant therapy. • CD3+ TILs rate was not prognostic for patients with stage II colon cancer who had adjuvant therapy. • Low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::086c6df88bf100ea58efd73d926f72a5
http://europepmc.org/articles/PMC7750416
http://europepmc.org/articles/PMC7750416
Autor:
Virginia Livellara, Andrea Giovanni Multari, Guido Francini, Stefano Lazzi, Luciana Messuti, Fang-Shu Ou, Edoardo Francini, Sara Cherri, Joleen M. Hubbard, Roberto Petrioli, Guido Pesola, Steven R. Alberts, Harry H. Yoon, Elena Colombo, Eric G. Wolfe, Serena Bazzurri, Miano Salvatora
Publikováno v:
Journal of Clinical Oncology. 38:167-167
167 Background: Previous studies have reported high TILs are a favorable prognostic factor in stage II CC. However, whether the impact of TILs on overall survival (OS) differs among pts who did or did not receive ADJ is still to be determined. We ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69bd8be16a1dd1dbb45d28384057b7e3
https://doi.org/10.1200/jco.2020.38.4_suppl.167
https://doi.org/10.1200/jco.2020.38.4_suppl.167